Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Short Interest Down 7.8% in July
Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) was the recipient of a large drop in short interest in July. As of July 15th, there was short interest totalling 87,000 shares, a drop of 7.8% from the June 15th total of 94,400 shares. Based on an average daily trading volume, of 24,600 shares, the days-to-cover ratio is presently 3.5 days. Approximately 1.0% of the shares of the stock are sold short.
A number of research analysts have weighed in on the stock. TheStreet raised shares of Medpace from a “c” rating to a “b-” rating in a research note on Wednesday, April 10th. Zacks Investment Research raised shares of Investors Real Estate Trust Reit from a “sell” rating to a “hold” rating in a research note on Thursday, May 23rd.
Shares of CPIX stock traded up $0.08 during trading on Tuesday, hitting $5.76. 15,623 shares of the stock traded hands, compared to its average volume of 33,106. The company has a market capitalization of $90.13 million, a price-to-earnings ratio of -48.00 and a beta of 0.14. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.07 and a quick ratio of 1.67. The firm’s fifty day moving average price is $6.07. Cumberland Pharmaceuticals has a 52-week low of $4.83 and a 52-week high of $7.00.
In other Cumberland Pharmaceuticals news, Director Gordon R. Bernard sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $6.36, for a total value of $25,440.00. Following the transaction, the director now directly owns 86,319 shares of the company’s stock, valued at approximately $548,988.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gordon R. Bernard sold 8,876 shares of the firm’s stock in a transaction that occurred on Wednesday, June 19th. The stock was sold at an average price of $6.22, for a total transaction of $55,208.72. Following the completion of the transaction, the director now directly owns 95,388 shares in the company, valued at $593,313.36. The disclosure for this sale can be found here. Over the last ninety days, insiders purchased 17,284 shares of company stock worth $106,293 and sold 49,399 shares worth $303,917. Company insiders own 39.38% of the company’s stock.
A hedge fund recently bought a new stake in Cumberland Pharmaceuticals stock. Bailard Inc. bought a new stake in Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 14,516 shares of the specialty pharmaceutical company’s stock, valued at approximately $92,000. Bailard Inc. owned about 0.09% of Cumberland Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 31.72% of the company’s stock.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.
Recommended Story: What can cause a stock to outperform?
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.